UNIQUE POSSIBILITIES FOR USE OF DANISH HEALTHCARE DATA

Steen Hommel was appointed The State Secretary for Trade and Global Sustainability at the Ministry of Foreign Affairs of Denmark in 2020. Prior, he has served as the Director of the Department of Invest in Denmark & Innovation at the MFA in 2016-2019 and as the Royal Danish Ambassador to Poland in 2012-2016.

Thomas Senderovitz took over as Director General of the Danish Medicines Agency on 1 April 2016. His career includes more than 20 years working intensively with medicinal products and he has held several senior positions in international biopharmaceutical companies (Ferring Pharmaceuticals, UCB Pharma, Grünenthal GmbH). Most recently, he was a member of the management team of the global contract research organisation PAREXEL engaging in clinical research for pharmaceutical and biotechnological companies. Thomas previously worked at the Clinical Pharmacological Department at Bispebjerg Hospital in Copenhagen. Thomas is a member of EMAs Management Board and Chair of the HMA Management Group. He is member of the Reference Group for Crown Prince Frederik centre for Public Leadership and member of Dataetisk Råd.

Jesper Kjær is Director of Division, Data Analytics Center (DAC). Jesper brings long experience of data handing, analyses and data visualisation having worked in the academic environment and pharmaceutical industry, and he has developed IT systems for the World Health Organization and Rigshospitalet. Jesper has also led the development of risk-based monitoring IT in Novo Nordisk and has headed activities in EU Framework Programmes, TransCelerate Biopharma and HL7.

Thomas is Professor of pharmacoepidemiology at University of Southern Denmark and ‘head of research’ at Hospital Pharmacy Funen at Odense University Hospital. His research focuses on the use of drugs in its broadest sense. Typically, he uses ´real-world’ data from Danish or international health care registries, to study and identify effects as well as side effects of medicines. Using such data, he has published more than 200 papers in various medical journals.

ICDK SV builds bridges and facilitate partnerships between Danish and U.S. companies, research institutions and public stakeholders. Allan has previously worked for the Association of the Pharmaceutical Industry, the Society of Engineers and the Ministry of Higher Education and Science. He has 25 years of experience in the field of research policy and innovation and has in-depth knowledge about strategic planning of public research programs, research funding and foresight methods.